SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In fact, most of the included RCTs (published until 31 October 2020) are small with a short period of treatment and, most importantly, to date, there are no head-to-head or placebo-controlled RCTs testing the effect of SGLT-2 inhibitors on the histological features of NAFLD.